<DOC>
	<DOCNO>NCT01280240</DOCNO>
	<brief_summary>The purpose study assess Pharmakokinetic property iron isomaltoside 1000 ( MonoferÂ® ) dose 250 mg 500 mg patient suffer Chemotherapy Induced anemia .</brief_summary>
	<brief_title>Pharmacokinetic Study Iron Isomaltoside 1000 Administered 250 mg IV Bolus Injection 500 mg Intravenous Infusion Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Men woman , age 18 year . 2 . Weight 50 kg . 3 . Subjects diagnose nonhematological malignancy ( solid tumor ) receive chemotherapy least 1 day prior screen go receive least two chemotherapy cycle . 4 . Hb &lt; 12 g/dL . 5 . TfS &lt; 20 % . 6 . Serum Ferritin &lt; 800 ng/ml . 7 . An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 8 . Willingness participate inform consent . 1 . Anaemia cause primarily factor CIA . 2 . IV oral iron treatment within 4 week prior screen visit . 3 . Erythropoietin treatment within 4 week prior screen visit . 4 . Blood transfusion within 4 week prior screen visit . 5 . Imminent expectation blood transfusion part treat physician . 6 . Iron overload disturbance utilization iron ( e.g . haemochromatosis haemosiderosis ) . 7 . Drug hypersensitivity ( i.e . previous hypersensitivity Iron Dextran iron mono disaccharide complex ) . 8 . Known hypersensitivity excipients investigational drug product . 9 . Subjects history multiple allergy . 10 . Decompensated liver cirrhosis hepatitis ( alanine aminotransferase ( ALAT ) &gt; 3 time upper normal limit ) . 11 . History Immunocompromise and/or history Hepatitis B and/or C. 12 . Active acute chronic infection ( assessed clinical judgement deem necessary investigator supply white blood cell ( WBC ) Creactive protein ( CRP ) ) . 13 . Rheumatoid arthritis symptom sign active joint inflammation . 14 . Pregnant breast feed woman . 15 . Women child bear potential use safe contraceptive method ( e.g . intrauterine device , oral contraceptive surgically sterilize ) plan become pregnant within study period . 16 . Planned elective surgery study . 17 . Participation clinical study ( except chemotherapy protocol ) within 3 month prior screen . 18 . Untreated B12 folate deficiency . 19 . Any medical condition , opinion Principal Investigator , may cause subject unsuitable completion study place subject potential risk study . Example , Uncontrolled Hypertension , Unstable Ischemic Heart Disease Uncontrolled Diabetes Mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>anemia</keyword>
	<keyword>cancer</keyword>
	<keyword>CIA</keyword>
</DOC>